The drug is the generic version of Celebrex, which is indicated for the relief of the signs and symptoms of osteoarthritis, rheumatoid arthritis, ankylosing spondylitis and for the
As part of the deal, REGENX has granted Voyager a non-exclusive worldwide license, as well as sublicensing rights, to its NAV vectors for the treatment of ALS, FA
By using its T-cell receptor (TCR) engineering technology, Adaptimmune has created TCRs which are deployed to target the cancer testis antigen, NY-ESO-1, and other targets. The company’s trials
The company is carrying out the development of the RSV vaccine, as part of the TechnoVax program, using its proprietary VLP technology, which is a new way to
The results showed that the combination was generally well tolerated and produced evidence of clinical response. In the trial, 42% of immunotherapy-naïve patients who received ipilimumab with INCB24360
Around 10,000 patients with severe burns are hospitalized every year in South Korea and primarily are treated at about 10 burn centers. The easy-to-use, topically-applied pharmaceutical product ‘NexoBrid’
The Phase I trial is designed to assess the safety, tolerability and initial efficacy of altiratinib in these patients. In preclinical studies, altiratinib has been shown to exhibit
Nuvigil is a prescription medicine indicated to improve wakefulness in adult patients with excessive sleepiness associated with obstructive sleep apnea (OSA), shift work disorder (SWD) or narcolepsy. As
The Phase III trials of subcutaneous ofatumumab in relapsing-remitting multiple sclerosis (RRMS) are expected to start in 2015, following encouraging data from a Phase II trial reported in
The company said that a six-month review period has been assigned for the Lemtrada sBLA and it expects FDA action on this in the fourth quarter. The sBLA
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.